NUVB — Nuvation Bio Inc. stock price, charts and financials

QT79Nuvation Bio Inc.

Nuvation Bio Inc. (NYSE: NUVB) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
6.50
-0.10-1.52%
OverviewShort InterestFilings
NUVBQT79Nuvation Bio Inc.·NYSE
6.50-1.52%
News
Down 1.5% — Nuvation Bio Q2 Earnings Call Highlights (marketbeat.com).
Medium confidence
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Premium shows the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands ofhistorical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
ADMA-1.67%$9.73URGN-1.72%$46.15SION-91.58%$4.30VCEL-0.88%$44.69PVLA-1.92%$154.74SLS-5.95%$11.29VERA-4.50%$31.41HRMY+1.98%$39.17
Snapshot
Index-P/E-EPS (ttm)-0.43Insider Own43.75%Shs Outstand347.20MPerf Week4.27%
Market Cap2.29BForward P/E-EPS next Y-0.24Insider Trans-0.33%Shs Float253.59MPerf Month8.02%
Enterprise Value2.29BPEG-EPS next Q-Inst Own-Short Float21.95%Perf Quarter37.21%
Income-149.18MP/S13.49EPS this Y19.96%Inst Trans-Short Ratio9.29Perf Half Y17.44%
Sales169.90MP/B9.07EPS next Y29.19%ROA-20.12%Short Interest55.67MPerf YTD-26.34%
Book/sh-P/C-EPS next 5Y-ROE-49.73%52W High9.60 -32.31%Perf Year180.85%
Cash/sh-P/FCF-EPS past 3/5Y-ROIC-20.68%52W Low2.15 202.75%Perf 3Y260.66%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin93.94%Volatility6.21% 6.02%Perf 5Y-23.61%
Dividend TTM-EV/Sales13.45EPS Y/Y TTM79.62%Oper. Margin-81.00%ATR (14)0.40Perf 10Y-
Dividend Ex-Date-Quick Ratio8.14Sales Y/Y TTM1687.50%Profit Margin-88.19%RSI (14)58.46Recom2.20
Dividend Gr. 3/5Y-Current Ratio8.37EPS Q/Q106.25%SMA204.92%Beta1.49Target Price20.50
Payout0.00%Debt/Eq0.99Sales Q/Q2666.67%SMA5015.29%Rel Volume0.90Prev Close6.59
Employees298LT Debt/Eq0.01EarningsNov 02SMA20014.41%Avg Volume6.42MPrice6.50
IPO DateAug 26, 2020Option/ShortYes / YesEPS/Sales Surpr.135.66% 25.68%Net Debt/EBITDA0.05Volume5,771,896Change-1.52%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-07-26ReiteratedRBC CapitalOutperform$19 → $20
Jul-27-26ReiteratedHC Wainwright & Co.Buy$17 → $21
Jul-07-26ReiteratedRBC CapitalOutperform$12 → $19
Jan-27-26ReiteratedTruist Financial$11 → $13
Jan-21-26ReiteratedRBC CapitalOutperform$5.00 → $12
Jan-12-26ReiteratedHC Wainwright & Co.Buy$18 → $17
Jan-07-26ReiteratedUBS$10
Dec-11-25ReiteratedHC Wainwright & Co.Buy$10 → $18
Dec-01-25ReiteratedHC Wainwright & Co.Buy$7.00 → $10
Nov-24-25InitiatedTruistBuy$11
Latest News
Aug-08-26
Aug-08-2605:04PM
Nuvation Bio Q2 Earnings Call Highlightsmarketbeat.com
Aug-06-26
Aug-06-2612:14PM
Nuvation Bio Inc. (NUVB) Q2 2026 Earnings Call Transcriptseekingalpha.com
10:51AM
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimateszacks.com
07:30AM
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Updateprnewswire.com
Aug-04-26
Aug-04-2608:12AM
Nuvation Bio Announces New Subgroup Analyses Of Phase 2 TRUST-I And TRUST-II Data For IBTROZI In ROS1+ NSCLC Will Be Presented At WCLC And ESMOBenzinga
08:00AM
Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congressesprnewswire.com
Aug-03-26
Aug-03-2611:35AM
4 Biotech Stocks Likely to Outpace Q2 Earnings Estimateszacks.com
Jul-30-26
Jul-30-2611:06AM
Nuvation Bio Inc. (NUVB) Expected to Beat Earnings Estimates: Should You Buy?zacks.com
Jul-29-26
Jul-29-2610:56AM
Wall Street Analysts See a 94.32% Upside in Nuvation Bio (NUVB): Can the Stock Really Move This High?zacks.com
Jul-27-26
Jul-27-2608:21AM
HC Wainwright & Co. Maintains Buy on Nuvation Bio, Raises Price Target to $21Benzinga
Jul-22-26
Jul-22-2604:05PM
Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026prnewswire.com
Jul-21-26
Jul-21-2611:10AM
Nuvation Bio (NUVB) Soars 7.9%: Is Further Upside Left in the Stock?zacks.com
Jul-20-26
Jul-20-2611:44AM
Why Is Nuvation Bio Stock Gaining Monday?Benzinga
08:00AM
Nuvation Bio Announces Positive Updated Phase 2 Data and Expansion of Safusidenib Clinical Program with Two New Studies to Explore Broad Spectrum of IDH1-Mutant Gliomaprnewswire.com
Jul-07-26
Jul-07-2612:18PM
RBC Capital Maintains Outperform on Nuvation Bio, Lowers Price Target to $19Benzinga
Company

Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6. The company's development pipeline further encompasses NUV-868, an orally administered, selective small molecule BET inhibitor that epigenetically influences proteins critical for tumor proliferation and cellular differentiation; NUV-569, a unique oral small molecule targeting the Wee1 kinase to facilitate DNA damage repair; and NUV-1182, an antagonist of adenosine receptors. Additionally, Nuvation Bio is progressing a sophisticated drug-drug conjugate (DDC) platform, engineered to deliver a poly ADP ribose polymerase (PARP) inhibitor in conjunction with existing anti-cancer warheads, particularly for the treatment of ER-positive breast and ovarian cancers. Established in 2018, the firm was initially named RePharmation Inc. before rebranding as Nuvation Bio Inc. in April 2019, and its central operations are based in New York, New York.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue170638——————
Cost of Goods Sold Incl. D&A1087——————
Gross Profit160541——————
Selling, General and Administrative Excl. Other15815269——————
Research and Development129115524——————
Other Operating Expense1010——————
Operating Income-137-213-593——————
Interest Expense28140——————
Unusual Expense
—————————
Non-Operating Income (Expense)142225——————
Net Income Before Taxes-151-205-568——————
Income Taxes
000——————
Consolidated Net Income-151-205-568——————
Net Income From Continuing Operations-151-205-568——————
Net Income-151-205-568——————
EPS (Recurring)-0.43-0.60-2.11——————
EPS (Basic, Before Extraordinaries)-0.43-0.60-2.11——————
EPS (Diluted)-0.44-0.60-2.11——————
EBITDA-127-189-567——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio13.3348.6489.44——————
Gross Margin94.1285.7112.50——————
Operating Margin-80.59-338.10-7,412.50——————
Net Margin-88.82-325.40-7,100.00——————
Shares Outstanding349342269——————
Market Capitalization2,2673,064716——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
$10.71$8.17$5.63$3.08$0.54● Close Price0.00M1.01M2.02M3.03M4.04MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Sauvage PhilippeChief Financial OfficerJul 15 '26Option Exercise2.1740,00086,80054,131Jul 17
Markel StacyCHIEF PEOPLE OFFICERJun 23 '26Option Exercise1.83125,000229,250157,591Jun 24
Wentworth KerryCHIEF REGULATORY OFFICERJun 23 '26Sale6.0263,000379,19153,000Jun 24
Sauvage PhilippeChief Financial OfficerJun 23 '26Option Exercise2.1747,668103,44060,341Jun 24
Sauvage PhilippeChief Financial OfficerJun 23 '26Sale6.0147,668286,37012,673Jun 24
Markel StacyCHIEF PEOPLE OFFICERJun 23 '26Sale6.03125,000753,18832,591Jun 24
Wentworth KerryCHIEF REGULATORY OFFICERJun 23 '26Option Exercise2.9363,000184,590116,000Jun 24
Mashal RobertDirectorJun 09 '26Buy4.7325,000118,250225,000Jun 11
Wentworth KerryCHIEF REGULATORY OFFICERApr 17 '26Option Exercise2.9336,750107,67889,750Apr 21
Wentworth KerryCHIEF REGULATORY OFFICERApr 17 '26Sale5.0136,750184,27953,000Apr 21
Liu DongfangCHIEF MEDICAL OFFICERApr 17 '26Option Exercise1.9450,00097,00068,000Apr 21
Liu DongfangCHIEF MEDICAL OFFICERApr 17 '26Sale5.0250,000251,00018,000Apr 21
Wentworth KerryCHIEF REGULATORY OFFICERApr 06 '26Option Exercise1.91200,000381,000253,000Apr 08
Wentworth KerryCHIEF REGULATORY OFFICERApr 06 '26Sale4.52200,000903,56053,000Apr 08
Liu DongfangCHIEF MEDICAL OFFICERDec 01 '25Option Exercise2.93150,000439,500168,000Dec 03
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.